Novo and Anthropic describe the same deal on two scales

Novo, which dropped the Nordisk from its name on 14 September, said two days later that it will work with Anthropic on drug discovery, putting Claude Science into scientific reasoning for research and development and into agentic software engineering. It starts in selected R&D workflows, and the announcement names data governance and human oversight alongside the capability rather than in a footnote at the end. What stands out is that the two chief executives describe the same agreement on entirely different scales. Novo's Mike Doustdar says AI can “increase productivity in R&D and compress the path from research to marketed product”, and calls the partnership a testament to the ambition “to become the world's most AI-driven healthcare company”. Anthropic's Dario Amodei says AI has the potential to “compress a century's worth of biological and medical breakthroughs into a decade”. One is an operating claim with a workflow attached to it, the other is a claim about the field. Our reading is that this gap is there to be managed rather than resolved. Partnerships of this kind carry two promises, and the one that gets measured afterwards is almost always the narrower one. (Novo)